Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 1
2010 1
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study.
Zeymer U, Huber K, Fu Y, Ross A, Granger C, Goldstein P, van de Werf F, Armstrong P; (for the ASSENT-4 PCI Investigators). Zeymer U, et al. Eur Heart J Acute Cardiovasc Care. 2012 Jun;1(2):136-42. doi: 10.1177/2048872612447069. Eur Heart J Acute Cardiovasc Care. 2012. PMID: 24062901 Free PMC article.
Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.
Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Lancet. 2006 Feb 18;367(9510):569-78. doi: 10.1016/S0140-6736(06)68147-6. Lancet. 2006. PMID: 16488800 Clinical Trial.
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis.
Sinnaeve PR, Ezekowitz JA, Bogaerts K, Droogne W, Jarai R, Huber K, Granger CB, Desmet WJ, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI Investigators. Sinnaeve PR, et al. Eur Heart J. 2009 Sep;30(18):2213-9. doi: 10.1093/eurheartj/ehp246. Epub 2009 Jul 8. Eur Heart J. 2009. PMID: 19586960 Clinical Trial.
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial.
Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Jarai R, et al. Crit Care Med. 2010 Sep;38(9):1793-801. doi: 10.1097/CCM.0b013e3181eaaf2a. Crit Care Med. 2010. PMID: 20562693 Clinical Trial.